These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 8182001)

  • 1. Administering amphotericin B--a practical approach.
    Khoo SH; Bond J; Denning DW
    J Antimicrob Chemother; 1994 Feb; 33(2):203-13. PubMed ID: 8182001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
    Maharom P; Thamlikitkul V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline.
    Branch RA; Jackson EK; Jacqz E; Stein R; Ray WA; Ohnhaus EE; Meusers P; Heidemann H
    Klin Wochenschr; 1987 Jun; 65(11):500-6. PubMed ID: 3475498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid formulations of amphotericin B.
    Jones E; Goldman M
    Cleve Clin J Med; 1998 Sep; 65(8):423-7. PubMed ID: 9769563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrotoxicity in the setting of invasive fungal diseases.
    Ullmann AJ
    Mycoses; 2008; 51 Suppl 1():25-30. PubMed ID: 18471158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deoxycholate amphotericin B and nephrotoxicity in the pediatric setting.
    Bes DF; Rosanova MT; Sberna N; Arrizurieta E
    Pediatr Infect Dis J; 2014 Aug; 33(8):e198-206. PubMed ID: 24618932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation.
    Branch RA
    Arch Intern Med; 1988 Nov; 148(11):2389-94. PubMed ID: 3056312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amphotericin B: 30 years of clinical experience.
    Gallis HA; Drew RH; Pickard WW
    Rev Infect Dis; 1990; 12(2):308-29. PubMed ID: 2184499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
    Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
    N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-based formulations of amphotericin B.
    Plotnick AN
    J Am Vet Med Assoc; 2000 Mar; 216(6):838-41. PubMed ID: 22570893
    [No Abstract]   [Full Text] [Related]  

  • 11. [Amphotericin B deoxycholate prescription and adverse events in a Chilean university hospital].
    Quinteros A R; Fica C A; Abusada A N; Muñoz C L; Novoa M C; Gallardo A C
    Rev Chilena Infectol; 2010 Feb; 27(1):25-33. PubMed ID: 20140311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical guidelines for preparing and administering amphotericin B.
    Kintzel PE; Smith GH
    Am J Hosp Pharm; 1992 May; 49(5):1156-64. PubMed ID: 1595747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid formulations of amphotericin B.
    Dix SP; Andriole VT
    Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
    Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
    Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex.
    Craddock C; Anson J; Chu P; Dodgson A; Duncan N; Gomez C; Mehta J; Sadullah S; Subudhi C; Yin JL
    Expert Opin Drug Saf; 2010 Jan; 9(1):139-47. PubMed ID: 19947901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity?
    Karimzadeh I; Farsaei S; Khalili H; Dashti-Khavidaki S
    Expert Opin Drug Saf; 2012 Nov; 11(6):969-83. PubMed ID: 22950480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amphotericin B toxicity reduced by administration in fat emulsion.
    Anderson RP; Clark DA
    Ann Pharmacother; 1995 May; 29(5):496-500. PubMed ID: 7655134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-based amphotericin B for the treatment of fungal infections.
    Slain D
    Pharmacotherapy; 1999 Mar; 19(3):306-23. PubMed ID: 10221369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
    Wade RL; Chaudhari P; Natoli JL; Taylor RJ; Nathanson BH; Horn DL
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amphotericin B lipid preparations: what are the differences?
    Adler-Moore JP; Proffitt RT
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():25-36. PubMed ID: 18430127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.